5 questions answered from cited research · Plain language
Yes, a high neutrophil-to-lymphocyte ratio (NLR) is linked to a higher risk of developing brain metastasis in lung cancer patients, according to a meta-analysis and other studies.
Read the full answer →Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and intracranial responses, though resistance can develop.
Read the full answer →Yes, stereotactic radiotherapy is an effective treatment for brain metastases, offering high local control rates and preserving cognitive function.
Read the full answer →Lung cancer brain metastasis is driven by tumor cells co-opting brain developmental pathways, secreting exosomal CEMIP and LCN2, and recruiting astrocytes and macrophages to create a supportive niche.
Read the full answer →Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor; targeted therapies like osimertinib show high intracranial response rates.
Read the full answer →